anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: The prognosis of patients with Relapsed/Refractory Osteosarcoma (R/R OS) remains dismal without an agreement on systemic therapy. The use of High-Dose Ifosfamide (14 g/sqm) with an external pump in outpatient setting (14-IFO) in R/R OS patients is limited. This study represents the first retrospective cohort analysis focused on evaluating the activity and toxicity of 14-IFO in this setting.
PATIENTS AND METHODS: The study investigated 14-IFO activity, in terms of tumour response according to RECIST 1.1 criteria, as well as survival rates and toxicity, according to CTCAE v.5.
RESULTS: The trial enrolled 26 patients with R/R OS. The Overall Response Rate (ORR) and Disease Control Rate (DCR) obtained was 23% and 57.5%, respectively. Patients with relapsed OS showed a higher ORR (45%) and DCR (82%) compared to refractory patients, irrespective of the number of prior treatment lines received. The achievement of disease control with 14-IFO administration enabled 27% of patients to undergo new local treatment. Four-month Progression-Free Survival (PFS) was 54% for all patients and 82% for the relapsed OS sub-group. Median Overall Survival (OSurv) was 13.7 months, with 1-year OSurv of 51% for all patients and 71% for relapsed patients. Age over 18 years and the presence of refractory disease were identified as negative prognostic factors for this patient cohort. A total of 101 cycles were evaluated for toxic assessment, demonstrating a tolerable profile without grade 3-4 non-haematological toxicities.
CONCLUSIONS: 14-IFO should be considered a viable treatment option for R/R OS, particularly due to its well tolerated toxicity profile and the potential for home-administration, which can improve patient quality of life without compromising efficacy.
Our ultimate research goal is to develop and validate a preventive strategy for PTSD. We aim to 1) demonstrate neurophysiological evidence (using fMRI) of preventive CBTm classes for PTSD, and 2) validate the utility of the proposed imaging-based biomarker for PTSD-related resiliency. Emerging evidence suggests that a program such as CBTm classes could promote resiliency to PTSD in healthy individuals at high risk for trauma exposure. Further, our preliminary brain imaging data analysis suggests that we can quantitate the brain connectivity pattern that may reflect resilience to PTSD. We thus hypothesize that CBTm will increase the PTSD resilience-related brain connectivity pattern expression.

In this novel pilot imaging study, we will recruit 40 PSP without PTSD or other mental disorder from 120 participants participating in our larger clinical trial. Twenty will be from each arm (CBTm and wait-list). The effect of CBTm on fMRI-based measures will be compared between arms.
FIELD: medicine, pharmaceutics. ^ SUBSTANCE: as an active ingredient, a pharmaceutical composition contains 6,7; 15; 16-dimethylene-3-oxo-17-preg-4-ene-21,17-carbolactone (drospirenone, DRSP) together with a pharmaceutically acceptable excipient or carrier. Said composition does not contain estrogen. Drospirenon is prepared in fast soluble dosage form. At least 70% of drospirenone are dissolved within 30 minutes. For ensuring said immediate release, drospirenone is either micronised, or in dosage form of surface area more than 10000 cm2/g, or is applied on the surface of particles of an inert carrier. The composition can be applied for endometriosis treatment and introduced in the form of a multiphase pharmaceutical preparation. ^ EFFECT: immediate-release drospirenone compositions under the invention exhibits high biological availability when administered orally. ^ 23 cl, 7 ex
<P>PROBLEM TO BE SOLVED: To provide a structured premix or a "delivering vehicle" composition designed as a carrier for improving the effects (e.g. by an improved attachment or other mechanisms) of each of hydrophobic useful agents (one or multiple kinds) (e.g. perfumery, beautifully whitening agent, etc.) originating from a body product composition (e.g. liquid and bar detergents, cream, emulsified liquid, a hair composition, a deodorant, etc.).  <P>SOLUTION: This body product composition having the structured useful agent carrier gives an improved attaching effect of the structured useful agent and improved effects of each of the hydrophobic useful agents (one or multiple kinds) in or on the carrier or in the presence of the structured useful agent carrier by preparing the structured useful agent compositions separately and combining with the body product composition (preferably the premix composition is in a molten or liquid state while being structured).  <P>COPYRIGHT: (C)2005,JPO&NCIPI
PURPOSE: A composition containing extracts of Eriobotrya japonica leaves and evening primrose seeds is provided to basically treat atopic dermatitis and to reduce allergic asthma or allergic rhinitis. CONSTITUTION: A composition for treating atopic dermatitis contains 20-50 parts by weight of an Eriobotrya japonica leaf extract and 10-40 parts by weight of an evening primrose seed extract as active ingredients. The composition is an emulsion form containing an aqueous layer and an oil layer. The extracts are dissolved in the aqueous layer. The aqueous layer contains 4% carbomer, polyquaternium, disodium laurase sulfosuccinate, cocamidopropyl betaine, dexpanthenol, silk amino acid, or 1,2-hexane diol. The oil layer includes jojoba oil, grape seed oil, or camellia oil. The oil layer further contains polysorbate 80 or rosemary oil. The composition further contains an emulsifier or a thickener. [Reference numerals] (AA) Relative ratio
A validation system includes at least one medical device for connection to a patient. Both the medical device and the patient have at least one identification marker. The validation system also has an identification device with a display that is configured to read the identification markers. The validation system further includes a server that communicates with the at least one medical device and the identification device. The server assigns the at least one medical device to a corresponding patient according to an assignment process. A reviewer reviews the assignment in a reviewing process that is independent of the assignment process. A method ensures that at least one item of patient information and/or location information is assigned to at least one medical device and that the assignment is reviewed.
Feedback may be a useful tool to optimize motor learning during practice. For example, feedback during practice that indicates the learner is performing above average (i.e. positive social comparative feedback) enhances motor skill learning and self-efficacy in healthy adults. While this type of feedback is hypothesized to promote learning in some tasks, no studies have examined whether positive social comparative feedback during practice promotes motor learning in a traditional motor sequence task. Therefore, the aim of the proposed project is to investigate the effect of positive social comparative feedback on the learning of a joystick-based motor sequence task in healthy adults. The study aims to recruit 60 participants who will be randomized into 1 of 3 feedback groups (control group, performance feedback, and performance plus positive feedback). Participants will practice a motor sequence task on a single day and then return for retention performance testing about 24 hours later. Changes in performance (response time to complete a sequence) and self-efficacy will be measured from baseline to 24 hours later at retention.
The present study was assumed that N‑acetylcysteine (AC) might improve cognitive function in adolescent rats with hypothyroidism through various mechanisms. Sixty adolescent rats were randomly divided into the following groups: Vehicle (received normal saline intraperitoneally (IP)); Propylthiouracil (PTU)‑induced hypothyroidism (0.05%, dissolved in drinking water); Hypothyroid rats were IP treated with different doses of AC (50, 100, and 150 mg/kg/day) for a period of six weeks; Normal rats treated with the highest doses of AC (150 mg/kg/day). Behavioral and biochemical analyses were studied for all groups. In the Morris water maze test, AC significantly reduced both the time to find the hidden platform and the distance travelled as compared to non‑treated hypothyroid rats. In the passive avoidance test, the latency of entering the dark chamber was significantly increased by AC, whereas decreased the time spent in the darkroom of the chamber compared to the hypothyroid rats. In biochemical results, AC reduced both malondialdehyde content and nitrite while increased the thiol content, catalase and superoxide dismutase enzymes activity in both the cortex and the hippocampus, and a notable improvement in brain‑derived neurotrophic factor (BDNF) levels in hippocampal tissues of the hypothyroid rats, while decreasing the level of interleukin‑6 in rat hippocampal region. Therefore, based on the results, the beneficial effects of AC on cognitive impairment in adolescent hypothyroid rats are probably related to its anti‑oxidant properties and notable improvement in BDNF levels.
Link prediction (LP) is a task for the identification of potential, missing and spurious links in complex networks. Protein-protein interaction (PPI) networks are important for understanding the underlying biological mechanisms of diseases. Many complex networks have been constructed using LP methods; however, there are a limited number of studies that focus on disease-related gene predictions and evaluate these genes using various evaluation criteria. The main objective of the study is to investigate the effect of a simple ensemble method in disease related gene predictions. Local similarity indices (LSIs) based disease related gene predictions were integrated by a simple ensemble decision method, simple majority voting (SMV), on the PPI network to detect accurate disease related genes. Human PPI network was utilized to discover potential disease related genes using four LSIs for the gene prediction. LSIs discovered potential links between disease related genes, which were obtained from OMIM database for gastric, colorectal, breast, prostate and lung cancers. LSIs based disease related genes were ranked due to their LSI scores in descending order for retrieving the top 10, 50 and 100 disease related genes. SMV integrated four LSIs based predictions to obtain SMV based the top 10, 50 and 100 disease related genes. The performance of LSIs based and SMV based genes were evaluated separately by employing overlap analyses, which were performed with GeneCard disease-gene relation dataset and Gene Ontology (GO) terms. The GO-terms were used for biological assessment for the inferred gene lists by LSIs and SMV on all cancer types. Adamic-Adar (AA), Resource Allocation Index (RAI), and SMV based gene lists are generally achieved good performance results on all cancers in both overlap analyses. SMV also outperformed on breast cancer data. The increment in the selection of the number of the top ranked disease related genes also enhanced the performance results of SMV.
BACKGROUND: Fatigue is the most commonly experienced symptom among people with multiple sclerosis (MS) and has the greatest impact in reducing quality of life. It is important to measure change in MS-related fatigue (MS-fatigue) in response to treatment, particularly the more recent disease modifying therapies (DMTs). To date there has been no systematic literature review of the patient reported outcome (PRO) tools used to measure MS- fatigue specifically in the context of DMTs.
METHODS: MEDLINE, Embase and Clinicaltrials.gov were searched from 01 January 2000 to 13 April 2021 to identify published studies of the treatment of MS with DMTs. Studies where MS-fatigue was measured as an outcome using a PRO tool were included in the review. Further literature searches were undertaken to provide information about the development and validation of each PRO tool.
RESULTS: 739 abstracts and 96 clinical trials were manually screened resulting in 68 articles for full text screening. 48 studies were identified for the review; 10 of these were RCTs that considered MS-fatigue as a secondary outcome (4 were Phase 3 trials). The PRO instruments used in the 10 RCTs were the Fatigue Scale for Motor and Cognitive Functions, Fatigue Impact Scale, Modified Fatigue Impact Scale, Fatigue Severity Scale, and Fatigue Symptoms and Impacts Questionnaire - Relapsing Multiple Sclerosis. The other 38 studies were all open-label, longitudinal, non-randomized studies and used the following PRO instruments in addition to those listed above: the Visual Analogue Scale for Fatigue, the Fatigue Descriptive Scale, Modified Fatigue Impact Scale (5 items) and the Würzburger Fatigue Inventory for MS. All these PRO tools were specifically developed for MS-fatigue. Of these 9 PRO tools, 7 were of good methodological quality according to the existing validation studies using the Consensus-based standards for the selection of health measurement instruments (COSMIN) check list and were used in the majority of the MS DMT studies (44/48, 92%). The median follow-up time from baseline to PRO measurement was 12 months (range 1-36 months). Most studies reported on MS fatigue in terms of its change from baseline and whether the change was statistically significant. 5 studies also reported what they considered to be a clinically meaningful difference.
CONCLUSIONS: Although fatigue has the greatest impact on quality of life in people with MS, few studies have rigorously investigated the impact of DMTs on fatigue. Comparisons between study outcomes using different PRO tools is challenging due to the variety of psychometric constructs addressed by the questionnaires and differences in the recall period for fatigue symptoms and the measurement scale. Furthermore most of the PRO tools used to quantify MS-fatigue in studies of DMTs are descended from PRO tools developed during the 1990s before DMTs emerged and before widespread patient involvement in PRO development. New PRO tools should involve patients in their development as recommended by the US Food and Drug Administration and the validation process should consider the sensitivity of the PRO tool to change in fatigue over time or between groups.
Left ventricular assist devices (LVAD) have become a life-saving therapy for patients with ACC/AHA stage D congestive heart failure (CHF). Despite longevity and improved quality of life, LVAD-supported patients are plagued with adverse events, the most debilitating of all is stroke. Ischemic and hemorrhagic strokes have been associated with hypertension (mean arterial pressure, or MAP \> 90 mmHg) in addition to out-of-range INR and aspirin doses. Strict blood pressure control has been shown in a recent randomized trial to confer a significant decline in stroke rates of patients implanted with the Heartware LVAD. Patients with poorly controlled hypertension are also at risk for inadequate left-ventricular unloading and worsening CHF due to the exquisite sensitivity to afterload of the continuous flow LVAD.

There are no guidelines for the use of anti-hypertensives in LVAD patients. Most are started on standard CHF therapies, though this practice varies greatly across LVAD centers. The angiotensin receptor blocker-neprilysin inhibitor sacubitril-valsartan (Entresto) is a potent anti-hypertensive mediation that was recently approved by the Food and Drug Administration for the treatment of patients with heart failure and low ejection fraction. We aim to randomly assign patients to receive Entresto or usual anti-hypertensive therapy for blood pressure control, then crossover to the other arm after 30 days. Daily blood pressure measurements will be performed and correlated with LVAD pump flows and waveform analysis.
C-PAN will be taken orally once daily in the morning prior to eating. The daily oral dose of C-PAN is 2000 mg (4 capsules of 500 mg each). Subjects will receive C-PAN exclusively for a run-in period of 3 to 7 days, and then a maintenance dose as long as the patient continues to receive SOC Nivolumab and Ipilimumab. Treatment will continue until unacceptable toxicity, progression of disease (PD), start of new anticancer therapy, or for a maximum of 1 year, whichever occurs earlier, and in the absence of criteria to discontinue C-PAN.
OBJECTIVES: Prompt HIV and STI diagnosis and treatment is a public health priority and relies on accessible testing. Technology-based approaches to distribute test kits have the potential to increase access to testing. We evaluated the acceptability and uptake of vending machines in publicly available settings in Brighton and Hove (BH) and Bristol, North Somerset and South Gloucestershire (BNSSG), to distribute HIV rapid self-test and STI self-sample kits.
METHODS: Seven machines were installed in BH and four in BNSSG. User characteristics, proportion of kits returned and test results, taken from the machine database and clinic records, combined with online questionnaires completed by self-recruited users and analysed using Stata and SPSS.
RESULTS: 2536 kits were dispensed over 12 months (April 2022 to March 2023). The STI self-sample kits were most popular (74% of vends). 78% of kits dispensed were among users aged 16-35 years and 56% identified as male. 68% and 59% of users had either not tested in the last 12 months or never tested for HIV and STIs, respectively. 51% of STI kits were returned via post, lower than the local online service (65%). 208 users completed questionnaires. Convenience, desire for instant access and increased confidentiality were the most common reasons for using machines. 92% of respondents thought the machines were user-friendly and 97% would recommend the service. Concerns about safety and privacy while using the machine were reported by 42% and 66% of respondents.
CONCLUSIONS: This study demonstrates that vending machines are an acceptable and effective means of accessing infrequent or never testers in the general population and can act as a horizontal intervention to tackle HIV and STIs. Research is needed to understand optimal machine locations to assure privacy and safety along with the long-term impact on sexual health services.
Participants will receive no intervention, except for a baseline follow-up at the start and again at the end of the first phase. 2 months after the end of the first intervention phase, participants in this group will receive the same mindfulness-based intervention for 4 weeks.
Individuals who screen positive will all move forward to receive this intervention. This includes connection to community partners with financial education and easily accessible resources, and a vocational navigation and support consultation for caregivers for 6-months.
This study will be carried out in two phases designed to achieve the objectives described above. The first phase will determine the feasibility of recording ipsilateral (contralesional) motor commands and use the signals to control a computer. This phase will involve recording EEG signals during the performance of real and imagined motor movements of both the impaired and non-impaired hand in stroke survivors. After recording the signals and analyzing the data, the signals will be used to try to control a cursor on a computer screen or a robotic hand. The second phase of the study will determine if the BCI system can be used to impact rehabilitation. Motor commands would be performed as in phase 1 to determine the accompanying EEG signals. The EEG signals would then be used to control stimulation of the impaired limb. Rehabilitation would be assessed by examining changes in commonly used functional motor scores.

The ultimate goal of this project is to develop a functioning and clinically feasible method for restoring function to motor-impaired stroke survivors. This ultimate goal will be approached through two different means. The first method is to develop a functioning brain-computer interface that operates based on cortical activity ipsilateral to an intended movement on the motor-impaired side of the body. And secondly, to develop new methods of rehabilitation that involve stimulating peripheral muscles based upon cortical activity ipsilateral to intended movements. Finally, the study seeks to assess changes in functional connectivity as a result of using a BCI device.
Before randomization, all patients are treated with intravenous unfractionated heparin (to a target aPTT of 70-90 s) or subcutaneous LMWH (the full therapeutic dose). For patients in the CDT group, the anticoagulation treatment was is described above; among CDT patients who received LMWH, the procedure should be postponed for 8 h after the last dose of LMWH. Patients in the standard care group continue therapeutic anticoagulation with either unfractionated heparin or LMWH. Subsequent change for oral anticoagulation is at the discretion of the treating physician (not earlier than 24 hours post-randomization).
Placebo (0.9% saline, sterile, unpreserved, USP/Ph.Eur.) - Intramuscular injections into affected neck muscles.
In one aspect, the present disclosure relates to compositions and methods for dispersing exiting salmonella biofilm and inhibiting salmonella biofilm formation. In various aspects, the disclosed compositions can be used in methods of treating persistent salmonella infections, including asymptomatic infections. Such infections may colonize various tissues, including the gallbladder. Methods of treating typhoid fever are also disclosed. Also disclosed are methods of reducing or preventing a secondary outbreak of typhoid fever by treating an asymptomatic subject who has no symptoms, previously had symptoms of typhoid fever. This abstract is intended as a scanning tool for the purpose of searching in the particular art and is not intended to be limiting of the present disclosure.